MARINUS PHARMACEUTICALS, INC.
DelistedCIK 1267813fmd_13KAKAP692058MNYPJEAYQ22APManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2024, 47 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | – | – | – | 2 | 15 | 25 | 31 |
| Cost of revenue | – | – | – | – | – | – | – | 1 | – | – |
| Gross profit | – | – | – | – | – | – | – | 14 | – | – |
| Research and development | 9 | 19 | 22 | 12 | 28 | 43 | 51 | 74 | 80 | 99 |
| Selling, general and administrative | – | – | – | – | – | – | – | 37 | 57 | 61 |
| Operating income | (12) | (24) | (28) | (19) | (37) | (54) | (68) | (97) | (113) | (131) |
| Interest expense | 0 | 0 | 0 | 0 | – | – | – | 3 | 11 | 17 |
| Interest and investment income | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 |
| Other non-operating income (expense) | – | (0) | (0) | (0) | (0) | (0) | (0) | 1 | (3) | 1 |
| Income before taxes | – | (25) | (29) | (19) | (37) | (54) | (67) | (99) | (16) | (143) |
| Income tax expense | – | – | – | – | – | – | – | – | 3 | (2) |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (20) | (141) |
| Net income | (11) | (25) | (29) | (19) | (37) | (54) | (67) | (99) | (20) | (141) |
| Net income to common shareholders | (13) | (25) | (29) | – | – | (54) | (76) | (99) | (20) | (141) |